Covid-19 roundup: In­ovio fi­nal­ly gets PhII rolling — but there's still a clin­i­cal hold; Low cost vac­cine en­ters PhI/II in In­dia

In­ovio has man­aged to con­vince the FDA to sign off on a Phase II tri­al of its Covid-19 vac­cine. But the Phase III por­tion re­mains clamped by a par­tial clin­i­cal hold more than a month af­ter it was first im­posed.

The lit­tle biotech said that reg­u­la­tors still have re­main­ing ques­tions about the de­vice that will be used to de­liv­er its can­di­date, INO-4800, di­rect­ly in­to the skin. The plan is “to re­solve the re­main­ing de­vice ques­tions dur­ing the con­duct of Phase 2 seg­ment and pri­or to the start of the Phase 3 seg­ment of the tri­al,” ac­cord­ing to a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER